These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9090301)

  • 41. Effect of clofibrate on plasma lipids of rat and rabbit.
    Byers SO; Friedman M
    Atherosclerosis; 1970; 11(3):373-82. PubMed ID: 5433083
    [No Abstract]   [Full Text] [Related]  

  • 42. Signaling molecules derived from the cholesterol biosynthetic pathway.
    Jackson SM; Ericsson J; Edwards PA
    Subcell Biochem; 1997; 28():1-21. PubMed ID: 9090289
    [No Abstract]   [Full Text] [Related]  

  • 43. [Lipid metabolism in peroxisomes].
    Suga T
    Tanpakushitsu Kakusan Koso; 1990 Jun; 35(8):1408-17. PubMed ID: 2374813
    [No Abstract]   [Full Text] [Related]  

  • 44. Unlimited mileage from telomerase?
    de Lange T; DePinho RA
    Science; 1999 Feb; 283(5404):947-9. PubMed ID: 10075559
    [No Abstract]   [Full Text] [Related]  

  • 45. Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions.
    Tamanoi F; Lu J
    Enzymes; 2013; 34 Pt. B():181-200. PubMed ID: 25034105
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy.
    Sebti SM; Hamilton AD
    Pharmacol Ther; 1997; 74(1):103-14. PubMed ID: 9336018
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 2-Arylindole-3-acetamides: FPP-competitive inhibitors of farnesyl protein transferase.
    Trotter BW; Quigley AG; Lumma WC; Sisko JT; Walsh ES; Hamann CS; Robinson RG; Bhimnathwala H; Kolodin DG; Zheng W; Buser CA; Huber HE; Lobell RB; Kohl NE; Williams TM; Graham SL; Dinsmore CJ
    Bioorg Med Chem Lett; 2001 Apr; 11(7):865-9. PubMed ID: 11294379
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?
    Cox AD; Der CJ
    Biochim Biophys Acta; 1997 Aug; 1333(1):F51-71. PubMed ID: 9294018
    [No Abstract]   [Full Text] [Related]  

  • 49. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts.
    Vogt A; Qian Y; McGuire TF; Hamilton AD; Sebti SM
    Oncogene; 1996 Nov; 13(9):1991-9. PubMed ID: 8934546
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Re: Blocking oncogenic Ras signaling for cancer therapy.
    Canevari S; Biocca S; Figini M
    J Natl Cancer Inst; 2002 Jul; 94(13):1031-2; author reply 1032. PubMed ID: 12096090
    [No Abstract]   [Full Text] [Related]  

  • 51. On the mechanism of hypocholesterolemic effects of polyunsaturated lipids.
    Paul R; Ramesha CS; Ganguly J
    Adv Lipid Res; 1980; 17():155-71. PubMed ID: 6992526
    [No Abstract]   [Full Text] [Related]  

  • 52. Mitogenic effect of lithium in FRTL-5 cells can be reversed by blocking de novo cholesterol synthesis and subsequent signal transduction.
    Tasevski V; Benn D; King M; Luttrell B; Simpson A
    Thyroid; 2000 Apr; 10(4):305-11. PubMed ID: 10807058
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells.
    Mazet JL; Padieu M; Osman H; Maume G; Mailliet P; Dereu N; Hamilton AD; Lavelle F; Sebti SM; Maume BF
    FEBS Lett; 1999 Oct; 460(2):235-40. PubMed ID: 10544242
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism.
    Cuthbert JA; Lipsky PE
    Cancer Res; 1997 Aug; 57(16):3498-505. PubMed ID: 9270019
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacological profile of tazasubrate, a new cholesterol-lowering agent.
    Schulze E; Obermaier J; Seyfried CA; Diekmann HW; Nowak H
    Atherosclerosis; 1986 Feb; 59(2):137-45. PubMed ID: 3008771
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cholesterol based antineoplastic strategies.
    Lenz M; Miehe WP; Vahrenwald F; Bruchelt G; Schweizer P; Girgert R
    Anticancer Res; 1997; 17(2A):1143-6. PubMed ID: 9137462
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
    Lingham RB; Silverman KC; Jayasuriya H; Kim BM; Amo SE; Wilson FR; Rew DJ; Schaber MD; Bergstrom JD; Koblan KS; Graham SL; Kohl NE; Gibbs JB; Singh SB
    J Med Chem; 1998 Nov; 41(23):4492-501. PubMed ID: 9804689
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-cancer drugs: molecular mechanisms of action.
    Isoldi MC; Visconti MA; Castrucci AM
    Mini Rev Med Chem; 2005 Jul; 5(7):685-95. PubMed ID: 16026315
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis.
    Kasiske BL; O'Donnell MP; Kim Y; Atluru D; Keane WF
    Kidney Int Suppl; 1994 Feb; 45():S51-3. PubMed ID: 8158898
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Importance of lipids in various metabolic aspects. 3. Regulation role of bile acids in the metabolism of cholesterol].
    Guzmán García J
    Gac Med Mex; 1967 Sep; 97(9):1136-41. PubMed ID: 4888371
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.